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Abstract
Pathogenic variants in the aryl hydrocarbon receptor-interacting protein (AIP) gene are increasingly recognised as a cause of 
familial isolated pituitary adenoma. AIP-associated tumours are most commonly growth hormone (GH) producing. In our 
cohort of 175 AIP mutation positive patients representing 93 kindreds, 139 (79%) have GH excess, 19 have prolactinoma (17 
familial and 2 sporadic cases) and out of the 17 clinically non-functioning tumours 4 were subsequently operated and found 
to be GH or GH & prolactin immunopositive adenoma. Here we report a family with an AIP variant, in which multiple fam-
ily members are affected by prolactinoma, but none with GH excess. To our knowledge this is the first reported family with 
an AIP pathogenic variant to be affected solely by prolactinoma. These data suggest that prolactinoma families represent a 
small subset of AIP mutation positive kindreds, and similar to young-onset sporadic prolactinomas, AIP screening would 
be indicated.
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Introduction
Although most pituitary tumours arise sporadically, in 
around 5% of cases there is a familial presentation. Famil-
ial isolated pituitary adenoma (FIPA) is defined as pituitary 
tumours occurring in two or more family members, in the 
absence of other recognised genetic syndromes [1]. Patho-
genic variants in the aryl hydrocarbon-interacting protein 
gene (AIP) have been increasingly recognised since their 
initial description in 2006, and are reported in up to 15% 
of FIPA families [2]. Pituitary tumours affect 17–23% of 
individuals with a pathogenic AIP variant [3, 4]. AIP asso-
ciated tumours are most commonly growth hormone (GH) 
producing; presenting at a younger age with large tumours 
that are relatively resistant to conventional medical therapy, 
with more male patients recognised [2]. Around 10% of AIP-
related pituitary tumours are solely prolactin producing [5, 
6]; all reported prolactinoma cases have either had family 
members with GH excess or were simplex cases of AIP 
mutation positive sporadic prolactinomas. Here we report a 
family with homogenous familial prolactinoma segregating 
a pathogenic AIP nonsense variant.
Case 1
A 46-year-old man presented in 2012, having been 
referred from ophthalmology with a 6-month history 
of visual blurring; Goldmann perimetry demonstrated 
bitemporal hemianopia. In retrospect, he also gave an 
approximately 6-month history of erectile dysfunction 
and 1-month history of headache. Biochemical testing 
revealed a serum prolactin of 199,490 mU/l (male ref-
erence range < 400 mU/l) and panhypopituitarism with 
serum testosterone 0.9 mmol/l (ref > 10), morning corti-
sol 60 nmol/l (ref > 250), free T4 10 pmol/l (ref 10–21) 
and IGF-1 27 µg/l (age-adjusted reference range 50–315). 
MRI scanning (Fig. 1) showed a large partly cystic, partly 
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solid mass measuring 61 × 38 × 24 mm; fluid levels within 
the cystic component were felt to be suggestive of haem-
orrhage and blood breakdown products. His growth and 
pubertal development had been normal, and his final adult 
height is 178 cm (mid-parental height 177.5). He is unmar-
ried and has never tried for children. He was treated with 
dopamine agonist therapy and at 7 years of follow-up he 
remains on 2 mg cabergoline weekly along with hydro-
cortisone, thyroxine and testosterone therapy. He has been 
unable to tolerate higher doses of cabergoline because of 
nausea. Imaging has shown significant reduction in tumour 
volume from an estimated 28 ml at diagnosis to 1 ml in 
2019 (Fig. 2); latest prolactin level is 5892 mU/l, and he 
has a minor ongoing visual field impairment. 
A family history of pituitary disease was elicited in 
2017, and targeted sequencing of the AIP gene identified 
a heterozygous nonsense variant, NM_003977.3:c.910C>T 
p.(Arg304Ter), in exon 6.
Case 2
His sister, at the age of 36 years, was referred to a different 
endocrine clinic in the same city in 2006 with a 9-month 
history of secondary amenorrhoea and galactorrhoea, which 
persisted after stopping citalopram. Her height is 167 cm 
(mid-parental height 163.5). Serum prolactin was elevated 
at 4437 mU/l (female reference range < 630 mU/l). MRI 
Fig. 1  Coronal (left) and 
sagittal (right) MRI images pre 
treatment
Fig. 2  Coronal (left) and sagit-
tal (right) MRI images follow-
ing treatment
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scanning revealed 2 discrete pituitary lesions measuring 9 
and 7.5 mm respectively. She was treated with cabergoline; 
menses returned and galactorrhoea ceased. Other pituitary 
function was normal, including normal IGF-1. Since then 
she has remained on cabergoline 1 mg weekly, latest prol-
actin is 929 mU/l at 13 years of follow-up, imaging in 2019 
(CT because of claustrophobia) has shown a single 8.5 mm 
lesion. She was found to be heterozygous for the same AIP 
variant in 2017.
She had two children when she was 25 and 27 years old: 
her son (Case 3) has the AIP variant, while her daughter did 
not inherit the variant.
Case 3
The 19-year-old son of Case 2 with the pathogenic AIP 
variant was identified on family screening in 2018. Growth 
and pubertal development had been normal and height at 
initial review was 180 cm (mid-parental height 176 cm). 
Prolactin was elevated at 2,131 mU/l in 2018 with morn-
ing testosterone of 7.7 nmol/l (reference > 10 nmol/l), IGF-1 
was 210 µg/l (age adjusted reference range 105–410) and 
MRI showed a 7  mm left-sided pituitary adenoma. He 
was treated with cabergoline initially 0.5 mg then 0.75 mg 
weekly. Imaging shows the lesion has not changed in size at 
18 months of follow-up; prolactin is 807 mU/l, his morning 
testosterone normalised to 15.8 nmol/l and cabergoline is 
being up-titrated.
Case 4
A 36-year-old second sister of Case 1 was referred in 2007 
with a 2 year history of secondary amenorrhoea. She had a 
significant history of anxiety and learning difficulties. Her 
height is 158 cm (mid-parental height 163.5 cm). Serum 
prolactin was 3936 mU/l which was felt, at least in part, to be 
related to anti-psychotic and antidepressant medications. She 
was unable to undergo MRI imaging due to claustrophobia, 
but in 2008 underwent CT pituitary which demonstrated an 
8 mm left-sided microadenoma. Remaining pituitary func-
tion was normal. Prolactin levels have remained elevated 
at 1685 mu/l at 12 years of follow-up despite 2 mg weekly 
cabergoline therapy; imaging in 2019 has shown stable 
appearances and she has been unable to tolerate higher doses 
of cabergoline due to mood disturbance. She is heterozygous 
for the same AIP variant.
There are two remaining female siblings (Fig. 3); one did 
not have the AIP variant, the other has not given her consent 
for genetic testing but has a serum prolactin within the refer-
ence range and she is of normal height.
Fig. 3  Pedigree. Filled symbols 
represent family members with 
a prolactinoma. Proband (case 
1) is indicated by the arrow. 
Square symbols: male, circles: 
female
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Discussion
A number of genetic syndromes are implicated in hereditary 
pituitary tumours, including Multiple Endocrine Neoplasia 
Types 1 and 4, Carney Complex, X-linked acrogigantism 
and McCune-Albright syndrome. Pathogenic variants in the 
AIP gene are now increasingly recognised in families with 
isolated pituitary tumour syndrome, typically causing gigan-
tism, with children as young as 4 years being reported to be 
affected. Pathogenic AIP variants have also been identified 
as founder variants, such as the one in Northern Ireland, 
arising over 100 generations ago and being responsible for 
numerous current and several historical Irish giant patients 
[3, 7]. Here we report a Scottish family, who are not known 
to be of Irish descent, with a history of prolactinoma. There 
is no family history of gigantism or acromegaly, and all 
affected patients had an IGF-1 within the age-adjusted ref-
erence range. We have identified 2 additional families with 
the same AIP variant born in the same city.
Much of the literature around AIP variants is focused on 
GH excess. Our large series of cases with AIP variants iden-
tified 10% of patients with prolactinomas, while tumours 
with negative GH and prolactin staining are exceedingly 
rare [6]. It is currently unclear why mutations in the widely 
expressed AIP gene leads to tumorigenesis in only soma-
totrophs and lactotrophs rather than other members of the 
PIT1 linage, other pituitary cell types or other organs. It 
is also uncertain why in this family, uniquely, none of the 
affected members developed GH excess, although, since 
none of the four affected family members underwent sur-
gery, immunohistochemical staining for GH has not been 
undertaken. The patient with the macroadenoma (Case 1) 
had no history of recent sudden-onset headache at diagnosis, 
but MRI features were compatible with haemorrhage which 
could be related to pituitary apoplexy, often described in AIP 
mutation positive cases [5, 6, 8–11]. Ongoing research using 
various animal models may help to explain these clinical 
observations in the future.
GH-secreting AIP mutation positive tumours are typically 
resistant to first generation somatostatin analogues, but the 
responsiveness of AIP mutation positive prolactinomas to 
dopamine agonists remains unclear. In our patients, although 
prolactin levels reduced in all 4 subjects, none showed nor-
malisation of prolactin levels at the doses patients were able 
to tolerate. Based on the lack of normalisation with < 2 mg 
cabergoline/week criteria [12], 2 of our 4 AIP mutation posi-
tive patients are resistant, while the other 2 cannot be fully 
assessed as they have not reached this cabergoline dose. 
Regarding tumour shrinkage, 3 out of the 4 patients showed 
reduction (but not disappearance) of tumour size, while there 
was no change in tumour size in one patient. These data 
indeed suggest a level of dopamine agonist resistance both 
for prolactin level and for tumour shrinkage.
In respect to other reported AIP kindreds, it is relevant 
that in this family there were 2 males and 2 females affected, 
with 3 of the 4 patients having a microadenoma (although 
one was diagnosed prospectively). In our overall cohort of 
175 AIP mutation positive patients representing 93 kindreds, 
139 (79%) have GH excess, 19 have prolactinoma (17 famil-
ial and 2 sporadic cases) and out of the 17 clinically non-
functioning tumours 4 were subsequently operated and found 
to be GH or GH & prolactin immunopositive adenoma. Out 
of 19 AIP mutation positive prolactinoma patients with a 
mean age of diagnosis of 29 years in our full AIP mutation 
positive cohort (including cases from this family) [6], there 
were 10 female patients, 12 with macroadenomas and 10 had 
surgery. An earlier study reported that of 13 AIP mutation 
positive prolactinoma patients with a mean age of diagnosis 
of 22 years, 10 were males, 12 had macroadenoma and 6 had 
surgery [2]. Among the 3 prolactinoma patients in a paediat-
ric prolactinoma cohort with unequivocally pathogenic AIP 
variants, 2 were males and all 3 had invasive macroadeno-
mas with a mean age of diagnosis at 16 years [13].
To our knowledge this is the first family with a patho-
genic AIP variant to be described who are affected solely 
by prolactinoma. These data suggest that pure prolactinoma 
families represent a small subset of AIP mutation positive 
kindreds. Genetic screening for AIP mutations is advised 
both in familial or sporadic young-onset prolactinoma and 
GH excess cases, as early diagnosis in family members leads 
to better clinical outcomes [6].
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